Greenhalgh, Janette; Bagust, Adrian; Boland, Angela; … - In: PharmacoEconomics 31 (2013) 5, pp. 403-413
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of rituximab (RTX) [Roche] to submit evidence for the clinical and cost effectiveness of RTX as first-line maintenance treatment for patients with follicular non-Hodgkin’s lymphoma (fNHL) whose disease...